Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In the last couple of years, the drug has grown rapidly in popularity among non-diabetes patients as a weight loss drug
These changes may assist short-term outcomes but generate fresh requirements when the drug ends
According to FDA prescribing information, these effects include nausea (12-30%), diarrhea (7-23%), vomiting (2-11%), constipation (5-17%), and abdominal pain (4-10%), with rates varying by dose and indication
Repeated compression of the dosing interval increases your average drug exposure beyond what was prescribed, elevates side effect risk, and disrupts the steady-state pharmacokinetics that your body has adapted to
In the AWARD-7 trial (which was not a CVOT) performed in T2DM subjects with moderate-to-severe CKD, once-weekly dulaglutide produced glycemic control similar to that achieved with insulin glargine, but showed evidence of reduced decline in eGFR (64)
Both peptides lack tumor-promoting activity in published studies, and neither affects cortisol, prolactin, or other hormonal axes
